U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269041) titled 'Immune Tolerance Induction After Liver Transplantation (iTILT)' on Nov. 21.
Brief Summary: This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."
Study Start Date: Dec., 2025
Study Type...